Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine

IRVINE, California, and AMSTERDAM, August 5, 2010 - Agendia, a world leader in molecular cancer diagnostics, today
announced the inauguration of a new state-of-the-art clinical genomics
laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were
located in Huntington Beach, CA. The new laboratory will further increase
capacity to support Agendia's strong commercial expansion in the U.S. market,
as well as the use of multiple Agendia tests in clinical research.
MammaPrint, the company's lead product and the only FDA-cleared breast cancer
recurrence test, is reimbursed by an increasing number of payers, covering
some 100 million lives today.

(Photo: www.newscom.com/cgi-bin/prnh/20100805/402822-a )

(Photo: www.newscom.com/cgi-bin/prnh/20100805/402822-b )

In addition, MammaPrint plays a central role in the recently
initiated I-SPY 2 trial, which is a revolutionary breast cancer trial and an
initiative of the Biomarkers Consortium, a unique public-private partnership
that includes the Food and Drug Administration, the National Institutes of
Health, and major pharmaceutical companies, led by the Foundation for the
National Institutes of Health. The I-SPY 2 trial, which will enroll patients
at 20 leading U.S. cancer research centers, will also rely on Agendia's
TargetPrint to provide objective, quantitative information about the
expression of the specific tumor-related proteins, ER, PR and Her-2neu, while
Agendia's DiscoverPrint will measure the expression of the whole genome for
all enrolled patients. These tests allow the study researchers to more
quickly identify which investigational drugs offer the most benefit for women
with certain tumor characteristics.

The new Irvine facility consists of corporate offices and a
15,000 square foot, state-of-the-art genomics laboratory. A large group of
California politicians and other VIPs attended the inauguration, including
the Mayor of Irvine, Sukhee Kang, and representatives of patient
organizations and clinicians.

"Our new genomics lab's capacity will allow us to meet the
increasing demand for MammaPrint across the United States and give physicians
and patients optimal test result turnaround and unmatched service and
support," said Dr. Bernhard Sixt, President and Chief Executive Officer.
"This expansion places us in an excellent position to continue making
advancements in molecular cancer diagnostics and equip oncologists with
powerful tools to use in the fight against breast cancer."

As the U.S. Food and Drug Administration prepares to regulate
Laboratory Developed Tests (LDTs) for the first time, Agendia finds itself in
an exceptionally strong position, having already secured 4 separate FDA
IVDMIA clearances for MammaPrint, establishing the company as the only
developer of a breast cancer recurrence test that is already validated by the
FDA. The launch of the new Irvine facility speaks to the company's growth and
success in the US marketplace.

Ongoing research and development commitments continue to
augment Agendia's ability to accurately predict breast cancer recurrence and
sub-typing, and help physicians tailor individual treatment plans to their
patients. Agendia's goal is to provide women with answers to crucial
treatment questions, such as how their breast cancer will respond to targeted
therapies or various chemotherapy regimens.

For more information, please visit www.agendia.com

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by
the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical
and analytical validation and reporting systems to ensure patient safety
issues are addressed. Highly accurate, MammaPrint identifies patients with
early metastasis risk - patients who are likely to develop metastases within
five years following surgery. Several authoritative studies have shown that
chemotherapy particularly reduces early metastasis risk. In planning
treatment, the MammaPrint test results provide doctors with a clear rationale
to assess the benefit of chemotherapy in addition to other clinical
information and pathology tests. All MammaPrint tests are conducted in
Agendia's CAP-accredited and CLIA compliant service laboratories.

About Agendia

Agendia is at the forefront of the personalized medicine revolution,
striving to bring more effective, individualized treatments within reach of
patients. Building on a cutting-edge genomics platform for tumor gene
expression profiling, the company's tests help physicians more accurately
tailor cancer treatments. Agendia markets four products, with several new
genomic tests under development. In addition, Agendia collaborates with
pharmaceutical companies to develop highly effective personalized drugs in
the area of oncology. Agendia is based in Irvine, California, and in
Amsterdam, The Netherlands.

Media Contacts: Hans Herklots, Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile, hans.herklots at agendia.com; Todd Aydelotte, Ricochet Public Relations, +1-212-679-3300 x111 Office, todd at ricochetpr.com